Drug Target Review

DECEMBER 13, 2024

Typically, these combinations include an immune checkpoint inhibitor (CPI; eg, anti-programmed cell death protein 1 [PD-1] / programmed cell death ligand 1 [PD-L1]) combined with other components such as chemotherapy, a targeted small molecule drug, novel CPIs, or ADCs. Discov Oncol. 2024;15(1):327. 2022;39(1):89-103.

Therapies 98

Therapies Treatment Clinical Trials Drugs 98

The Pharma Data

JANUARY 19, 2021

Its lead candidate is CLN-081, an oral small molecule designed to be a next-generation, irreversible EGFR inhibitor. Other products include CLNB-049, a bispecific antibody against FLT3 and CD3 and CLN-619, a monoclonal antibody that simulates NK and T-cell responses. This is planned to raise about $25 million.

Small Molecule 52

Small Molecule Trials Laboratories Immune Response 52

The Pharma Data

APRIL 22, 2023

These “acute inflammatory lesions” then attract other myeloid cells, as well as self-reactive T and B cells that belong to the immune system’s second arm, known as the “adaptive immune system” and directly attack the myelin covering. “Current MS therapies do not specifically target myeloid cells. .

Therapies 40

Therapies Immune Response Small Molecule Engineering 40

The Pharma Data

DECEMBER 15, 2020

Small Molecule Inhibitors. NMD670 is a first-in-class small molecule inhibitor of the muscle specific chloride ion channel, the ClC-1 ion channel. Oral, Small Molecules. KAN-101 is in a randomized, double-blind, placebo-controlled Phase I study, Assessment of KAN-101 in Celiac Disease.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

Codon

AUGUST 27, 2024

Extra pieces of data, including proteins, lipids, or small molecules, are helpful when a particular DNA sequence is difficult to amplify or isolate from a sample, or when sequencing results don’t point squarely at a single disease-causing organism. Cite: Allison Berke. “Defense-Forward Biosecurity.”

DNA 93

DNA Laboratories Hospitals Virus 93

NIH Director's Blog: Drug Development

MAY 21, 2020

One advantage of this class of therapeutics is that the timelines for their development, testing, and approval are typically shorter than those for drugs made of chemical compounds, called small molecules. In the U.S. Stay tuned for more information about these potentially significant advances in the next few months. medRxiv.

Virus 52

Virus Vaccine Laboratories Small Molecule 52

Vial

DECEMBER 11, 2023

The Food and Drug Administration (FDA) approved and recommended dozens of small-molecule drugs. Other inhibitors, currently in different stages of development (including clinical trials ), mainly target viral non-structural proteins or the internal ribosome entry site (IRES).

Clinical Research 52

Clinical Research Therapies Research Vaccine 52

The Pharma Data

SEPTEMBER 15, 2020

Based on the acceptable safety profile and the favorable immune response data, including the 4th dose response data, Pfizer received Breakthrough Therapy Designation. Internal Medicine. These results were presented in August at the Digital International Liver Congress 2020. approval in 2021.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

Codon

DECEMBER 12, 2024

The most obvious defense would not be vaccines, but rather antibiotics; small molecules that treat or prevent bacterial infections. After years of debate, an international pact limiting emissions of ozone-depleting substances was signed in 1987. But consider the international prohibition on experimenting with live smallpox.

DNA 102

DNA RNA Vaccine Virus 102

The Pharma Data

AUGUST 3, 2021

announced an exclusive collaboration focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immune responses. As part of Lilly’s response to the COVID-19 pandemic, and at the request of U.S. Gross margin as a percent of revenue was 79.3

Production 52

Production Marketing Research DNA 52

The Pharma Data

APRIL 27, 2021

up 60%) driven by increase disease and product awareness as well as adoption of new ISTH (International Society on Thrombosis and Haemostasis) TTP guidelines. MRT5500 (SP0254), an mRNA vaccine candidate against SARS-CoV-2, entered Phase 1/2 to assess safety, immune response and reactogenicity.

Vaccine 52

Vaccine Production FDA Disease 52

The Pharma Data

MAY 6, 2021

It is the decision of sovereign States to offer immunization to athletes and their delegations in accordance with their local guidance before travelling to Japan for the Tokyo Games. NEW YORK & MAINZ, Germany–(BUSINESS WIRE)– Pfizer Inc. The Pfizer-BioNTech COVID-19 Vaccine may not protect all vaccine recipients.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

DECEMBER 27, 2020

It is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory diseases. Transgene and BioInvent International received regulatory approval in Belgium for a Phase I/IIa trial of oncolytic Vaccinia virus BT-001. platforms and the human GM-CSF cytokine.

Trials 52

Trials Clinical Trials Therapies RNA 52

The Pharma Data

SEPTEMBER 8, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

SEPTEMBER 8, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. the United States. the United States.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

SEPTEMBER 9, 2020

Today’s decision is a further illustration of how collaboration and solidarity can help address a global health crisis as an international community,” said Ugur Sahin, M.D., During preclinical and clinical studies, BNT162b1 and BNT162b2 emerged as strong candidates based on assessments of safety and immune response.

Vaccine 52

Vaccine Clinical Trials Trials Government 52

The Pharma Data

JUNE 24, 2021

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer?BioNTech Deliveries to 47 countries and territories around the world are planned through June 2021 as part of the COVAX second round allocation of Pfizer-BioNTech COVID-19 Vaccine doses. The Pfizer?BioNTech

Government 52

Government Vaccine Clinical Trials Licensing 52